 SOUTH SAN FRANCISCO, Calif., April 16, 2021 PRNewswire -- IDEAYA Biosciences, Inc. NASDAQ: IDYA, a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced clinical data from the ongoing Phase 12 trial evaluating darovasertib IDE196 monotherapy and binimetinib combination therapy in patients with solid tumors, including Metastatic Uveal Melanoma MUM and Skin Melanoma ClinicalTrials.gov Identifier: NCT03947385. 